Literature DB >> 17351660

NA+- and K+-channels as molecular targets of the alkaloid ajmaline in skeletal muscle fibres.

O Friedrich1, F V Wegner, M Wink, R H A Fink.   

Abstract

BACKGROUND AND
PURPOSE: Ajmaline is a widely used antiarrhythmic drug. Its action on voltage-gated ion channels in skeletal muscle is not well documented and we have here elucidated its effects on Na(+) and K(+) channels. EXPERIMENTAL APPROACH: Sodium (I(Na)) and potassium (I(K)) currents in amphibian skeletal muscle fibres were recorded using 'loose-patch' and two-microelectrode voltage clamp techniques (2-MVC). Action potentials were generated using current clamp. KEY
RESULTS: Under 'loose patch' clamp conditions, the IC(50) for I(Na) was 23.2 microM with Hill-coefficient h=1.21. For I(K), IC(50) was 9.2 microM, h=0.87. Clinically relevant ajmaline concentrations (1-3 microM) reduced peak I(Na) by approximately 5% but outward I(K) values were reduced by approximately 20%. Na(+) channel steady-state activation and fast inactivation were concentration-dependently shifted towards hyperpolarized potentials ( approximately 10 mV at 25 microM). Inactivation curves were markedly flattened by ajmaline. Peak-I(K) under maintained depolarisation was reduced to approximately 30% of control values by 100 microM ajmaline. I(K) activation time constants were increased at least two-fold. Lower concentrations (10 or 25 microM) reduced steady-state-I(K) slightly but peak-I(K) significantly. Action potential generation threshold was increased by 10 microM ajmaline and repolarisation prolonged. CONCLUSIONS AND IMPLICATIONS: Ajmaline acts differentially on Na(+) and K(+) channels in skeletal muscle. This suggests at least multiple sites of action including the S4 subunit. Our data may provide a first insight into specific mechanisms of ajmaline-ion channel interaction in tissues other than cardiac muscle and could suggest possible side-effects that need to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351660     DOI: 10.1038/sj.bjp.0707194

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  Effects of ajmaline on contraction patterns of isolated rat gastric antrum and portal vein smooth muscle strips and on neurogenic relaxations of gastric fundus.

Authors:  Robert Patejdl; Alina Gromann; Dietmar Bänsch; Thomas Noack
Journal:  Pflugers Arch       Date:  2019-05-02       Impact factor: 3.657

2.  Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action.

Authors:  F Fischer; N Vonderlin; E Zitron; C Seyler; D Scherer; R Becker; H A Katus; E P Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-06       Impact factor: 3.000

Review 3.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

4.  Screening an In-House Isoquinoline Alkaloids Library for New Blockers of Voltage-Gated Na+ Channels Using Voltage Sensor Fluorescent Probes: Hits and Biases.

Authors:  Quentin Coquerel; Claire Legendre; Jacinthe Frangieh; Stephan De Waard; Jérôme Montnach; Leos Cmarko; Joseph Khoury; Charifat Said Hassane; Dimitri Bréard; Benjamin Siegler; Ziad Fajloun; Harold De Pomyers; Kamel Mabrouk; Norbert Weiss; Daniel Henrion; Pascal Richomme; César Mattei; Michel De Waard; Anne-Marie Le Ray; Christian Legros
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

Review 5.  The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!

Authors:  Michelle M Monasky; Emanuele Micaglio; Sara D'Imperio; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-12-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.